Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VTB reported for 7 months of 2023 by IFRS

8/31/23 VTBR

Phosagro summarizes the results of the ten-year investment cycle

8/31/23 PHOR

Salesforce reported 6 months of fiscal year 2024

8/31/23 CRM

Cherkizovo plans to increase the share of export revenues to 10%

8/31/23 GCHE

Board of Directors of Phosagro recommended that dividends be paid for 6 month 2023

8/30/23 PHOR

DZRD reported for 6 months of 2023 by IFRS

8/30/23 DZRD

SFI reported for 6 months of 2023 by IFRS

8/30/23 SFIN

Electrozinc reported for 6 months of 2023 by IFRS

8/30/23 ELTZ

VSZ reported for 6 months of 2023 by IFRS

8/30/23 VSYD

Artgen reported for 6 months of 2023 by IFRS

8/30/23 ABIO